AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19880456
Drug: Screening linked
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening linked to treatment options via referral and follow-up
Trial: 9707027
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (chemo)
Trial: 9707027
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and total body irradiation (chemo + TBI)
Trial: 3349312
Drug: Wedge resection/segmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wedge resection/segmental phenolization combination treatment (WR/SP)
Trial: 26286872
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (0.5 mg/kg)
Trial: 26286872
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate syrup (50 mg/kg)
Trial: 19778920
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment of non-IRA (CR group)
Trial: 8841153
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (25 mg/16 hr) during sauna session
Trial: 7884019
Drug: Fluvoxamine 150
RxNorm normalized name: fluvoxaMINE 150 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 150 mg per day
Trial: 6839004
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg single oral dose)
Trial: 6839004
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg single oral dose)
Trial: 31558376
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ivermectin 200 μg/kg
Trial: 31558376
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of ivermectin 200 μg/kg (given on days 1, 2, 15, and 16)
Trial: 26854246
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg daily)
Trial: 24280344
Drug: Cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (200 mg/day) for 6 months
Trial: 20956902
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg midazolam with 0.5% hyperbaric bupivacaine
Trial: 17959979
Drug: Morphine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine IV PCA
Trial: 16277588
Drug: Mechanical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical and chemical oral cleansing using povidone-iodine
Trial: 16277588
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral health care (POHC) administered by dental hygienists once a week for 24 months
Trial: 16277588
Drug: POHC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POHC treatment for 6 months in the winter season
Trial: 16406170
Drug: HPIV3cp45 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPIV3cp45 vaccine
Trial: 10828084
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose GH (1 U daily)
Trial: 10828084
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose GH (2 U daily)
Trial: 10828084
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose GH (after 12 months)
Trial: 8657857
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy with relaxation therapy and autogenic training
Trial: 8657857
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy with relaxation therapy and autogenic training
Trial: 1505610
Drug: 16-hour nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16-hour nicotine patch releasing 15 mg nicotine applied daily for 16 h over 12 weeks
Trial: 6412224
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg three times daily
Trial: 6345370
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg three times daily
Trial: 29438562
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine (n = 1002)
Trial: 29438562
Drug: Td vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td vaccine (n = 328)
Trial: 26305442
Drug: Classroom Communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classroom Communication Resource (CCR) intervention administered to 97 participants in the experimental group.
Trial: 20118780
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin threshold of 7.0 g/dL)
Trial: 20118780
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin threshold of 9.5 g/dL)
Trial: 12401733
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU vitamin E daily
Trial: 10064663
Drug: Cisapride (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.2 mg/kg 4 times daily for 2 weeks)
Trial: 29273477
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (Hb < 7.5 g/dL)
Trial: 29273477
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (Hb < 9.5 g/dL intraoperatively or postoperatively in ICU; Hb < 8.5 g/dL on the ward)
Trial: 25493193
Drug: L-tug lycosome
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tug lycosome formulation of dark chocolate (30 g daily)
Trial: 25493193
Drug: Regular dark
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dark chocolate (30 g daily)
Trial: 25493193
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate with 7 mg of lycopene
Trial: 15206992
Drug: Tetracycline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (500 mg 12 hourly for 7 days)
Trial: 11507213
Drug: ALVAC-HIV recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV recombinant canarypox vaccines
Trial: 9674400
Drug: Rapidly shaking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapidly shaking and pinching the skin during lidocaine injection
Trial: 8018904
Drug: MCNU-VMP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCNU-VMP therapy
Trial: 8018904
Drug: VMP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMP therapy
Trial: 162677
Drug: Viloxazine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine (150 mg daily)
Trial: 162677
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 mg daily)
Trial: 29126292
Drug: ZVIN (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZVIN (4 doses)
Trial: 28954982
Drug: Non-administration (control)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-administration (control)
Trial: 15608541
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluoxetine and cognitive-behavioral therapy
Trial: 1534422
Drug: Cefixime (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (400 mg or 800 mg single oral dose)
Trial: 1534422
Drug: Ceftriaxone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (250 mg single intramuscular dose)
Trial: 6378988
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg q.i.d. per os)
Trial: 6378988
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg b.i.d. per os)
Trial: 28948440
Drug: Intrauterine hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine hCG infusion prior to embryo transfer (ET)
Trial: 28948440
Drug: No hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hCG infusion prior to embryo transfer (ET)
Trial: 26681752
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (atorvastatin/niacin)
Trial: 26681752
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (Atorvastatin)
Trial: 24375159
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 400 mg three times daily for 2 months
Trial: 24375159
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 tablets/day) for 2 months
Trial: 17042717
Drug: Clodronate 800
RxNorm normalized name: clodronic acid 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 800 mg daily
Trial: 12059895
Drug: Propofol (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (Group P, bolus 1.5-2.0 mg/kg, maintenance 3.0-7.0 mg/kg/h) with remifentanil (10 microg/kg/h)
Trial: 8562234
Drug: Metoprolol 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 6.25 mg twice daily
Trial: 8562234
Drug: Celiprolol 25
RxNorm normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 25 mg daily
Trial: 2896383
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g daily for 4 weeks)
Trial: 668553
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg daily long-term)
Trial: 31923768
Drug: Metoprolol 25
RxNorm normalized name: metoprolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 25 mg and Aspirin 100 mg
Trial: 23577699
Drug: Morphine-induced postconditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-induced postconditioning (0.1 mg/kg)
Trial: 20078390
Drug: MNC+G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNC+G-CSF
Trial: 20078390
Drug: MNC-G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNC-G-CSF
Trial: 10741625
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 2 g cefpirome
Trial: 10741625
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 2 g cefpirome over 8 hours
Trial: 10741625
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefpirome
Trial: 10741625
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection and continuous infusion of cefpirome
Trial: 8199795
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy from a clinical psychologist
Trial: 2951093
Drug: Bread (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread (90 g)
Trial: 2951093
Drug: Spaghetti (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spaghetti (65 g)
Trial: 2951093
Drug: Potatoes (285
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potatoes (285 g)
Trial: 31752769
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy (PDT + anti-VEGF)
Trial: 31752769
Drug: Deferred combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred combination therapy (PDT + anti-VEGF)
Trial: 22949147
Drug: Aflibercept (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (4 mg/kg intravenously) plus FOLFIRI
Trial: 26228675
Drug: Fenofibrate (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (160 mg/d)
Trial: 8775611
Drug: Irrigation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigation with dilute povidone-iodine solution after primary reclosure (Group A)
Trial: 29202862
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy for Unusual Experiences (CBT-UED) plus routine care
Trial: 19933408
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy in patients with Chagas disease
Trial: 12100056
Drug: KLH-conjugated decapeptide
RxNorm normalized name: acetyl decapeptide-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLH-conjugated decapeptide vaccine (250 microg) administered intramuscularly, with three injections monthly and a booster 5 to 8 weeks later.
Trial: 12100056
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intramuscularly, with three injections monthly and a booster 5 to 8 weeks later.
Trial: 12100056
Drug: KLH-conjugated decapeptide
RxNorm normalized name: acetyl decapeptide-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLH-conjugated decapeptide vaccine (250 microg) administered intramuscularly.
Trial: 12100056
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intramuscularly.
Trial: 9590465
Drug: Calcipotriene 30
RxNorm normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriene 30 g per day (15 g ointment twice a day for 14 days)
Trial: 7871091
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of alpha-2 adrenoceptor antagonist
Trial: 2832091
Drug: DAMP-ES (schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAMP-ES (schedule I: daily x5, doses of 10-90 mg/m2 per day)
Trial: 2832091
Drug: DAMP-ES (schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAMP-ES (schedule II: 24-h continuous infusion, doses of 192 and 240 mg/m2)
Trial: 2832091
Drug: Recommended starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recommended starting doses for phase II studies
Trial: 12375799
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of taxanes and irinotecan
Trial: 11853793
Drug: Chloramphenicol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol (25 mg/kg 6 hourly)
Trial: 11853793
Drug: Benzylpenicillin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzylpenicillin (50 mg/kg 6 hourly) plus Gentamicin (7.5 mg/kg daily)
Trial: 26458124
Drug: Interferon beta‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1b (250 μg or 500 μg)
Trial: 21676368
Drug: Hydration plus
RxNorm normalized name: Biotrue Hydration Plus Multi-Purpose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration plus systemic hypothermia (33°C to 34°C) before first contrast injection and for 3 hours after the procedure
Trial: 19407711
Drug: Desvenlafaxine (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (fixed doses: 50, 100, 200, or 400 mg/day)
Trial: 19407711
Drug: Desvenlafaxine (flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (flexible doses: 100-400 mg/day)
Trial: 16940855
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg elemental zinc twice daily for 14 days)
Trial: 16940855
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsule for 14 days)
Trial: 8858666
Drug: BPIV-3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPIV-3 vaccine
Trial: 1518260
Drug: Postremission chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postremission chemotherapy (CT-MC)
Trial: 6434387
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nisoldipine after acute administration
Trial: 6434387
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nisoldipine at the end of three weeks of treatment (10 mg twice daily)
Trial: 6434387
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg verapamil three times daily
Trial: 31226936
Drug: Multimodal treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment: therapeutic workout program + medication review + diet adjustment + health education
Trial: 31226936
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: medication review + diet adjustment + health education (regular workout recommendations)
Trial: 29795561
Drug: rhTM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTM treatment
Trial: 25226757
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program (protocol-defined pharmacist care)
Trial: 19780875
Drug: Adefovir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir monotherapy (ADV)
Trial: 15591724
Drug: Modified mastectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified mastectomy with adjuvant chemo- or radiation therapy
Trial: 8041896
Drug: Preferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred treatment for glottic laryngeal cancer
Trial: 8041896
Drug: Treatment recommendations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment recommendations for patients vs self
Trial: 3276390
Drug: 9 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 9 months of chemotherapy according to a modified Rosen schedule
Trial: 3276390
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of chemotherapy followed by lung irradiation
Trial: 26680684
Drug: Methazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide (250 mg)
Trial: 26680684
Drug: Aminophylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (400 mg)
Trial: 26680684
Drug: Methazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methazolamide (250 mg) with Aminophylline (400 mg)
Trial: 24291456
Drug: Thrice-weekly structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly structured aerobic and resistance exercise intervention
Trial: 11772295
Drug: Therapies aimed
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies aimed at eradicating chronic infections
Trial: 7880675
Drug: Midline approach
RxNorm normalized name: amidoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midline approach with flexed lateral position (ML)
Trial: 1099032
Drug: Cream with
RxNorm normalized name: CREAM WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream with pH of 6
Trial: 31488402
Drug: Nebulised hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised hypertonic saline (HS) treatment (4 mL of 3% sodium chloride every 6 hours)
Trial: 25534727
Drug: LFF571 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFF571 (200 mg four times daily for 10 days)
Trial: 1322075
Drug: Vancomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (125 mg four times daily for 10 days)
Trial: 23587029
Drug: Baseline HDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline HDL < 1.21 mmol/l
Trial: 21440948
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atorvastatin and gemfibrozil